Tianeptine

Phase 2Small molecule

Pfizer

Tianeptine is one of 71 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

MedicationUnknown status

COVID-19Recruiting

Breast CancerPreclinical

Active, not recruiting

MedicationPreclinical

Unknown status

COVID-19Phase 2

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Preclinical

1 2

Voltaren

Novartis

Preclinical

1 3

Tianeptine

Pfizer

Phase 2

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

Duragesic-100

CCephalon

Preclinical

2 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Tricor

JJagotec

Preclinical

1 9

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Vfend

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

COVID-19

NCT06012552

Clinical

Trials by Indication[1]

Breast Cancer1 trial

The Efficacy of Tianeptine Versus Pregabalin on Acute and Chronic Post Mastectomy Pain After Breast Cancer Surgery.

Completed·NNational Cancer Institute, Egypt·N/A·NCT05935059·90 enrolled

Major Depressive Disorder1 trial

Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder

Completed·SSamsung Medical Center·Phase 4·NCT01309776·164 enrolled

COVID-191 trial

Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19.

Recruiting·MMilitary Institute od Medicine National Research Institute·Phase 2·NCT06012552·140 enrolled

Cohort Study1 trial

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

Completed· Pfizer logo

Pfizer··NCT04446039·370,212 enrolled

Bipolar Depression1 trial

Efficacy of Adjunctive Tianeptine in the Treatment of Bipolar Depression

Unknown status·HHospital de Clinicas de Porto Alegre·Phase 3·NCT00879372·13 enrolled

1 more indication

Medication1 trial

Brain Response to Serotonergic Medications in ASD

Unknown status·KKing's College London·N/A·NCT04145076·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Tianeptine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tianeptine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tianeptine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

Tianeptine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Breast Cancer1 trial

Major Depressive Disorder1 trial

COVID-191 trial

Cohort Study1 trial

Bipolar Depression1 trial

Medication1 trial

References

Drug Info

Quick Facts

Related News